316 related articles for article (PubMed ID: 23144198)
1. Lenalidomide as salvage treatment for multiple myeloma relapsing after allogeneic hematopoietic stem cell transplantation: a report from the French Society of Bone Marrow and Cellular Therapy.
Coman T; Bachy E; Michallet M; Socié G; Uzunov M; Bourhis JH; Lapusan S; Brebion A; Vigouroux S; Maury S; François S; Huynh A; Lioure B; Yakoub-Agha I; Hermine O; Milpied N; Mohty M; Rubio MT
Haematologica; 2013 May; 98(5):776-83. PubMed ID: 23144198
[TBL] [Abstract][Full Text] [Related]
2. Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial.
Kneppers E; van der Holt B; Kersten MJ; Zweegman S; Meijer E; Huls G; Cornelissen JJ; Janssen JJ; Huisman C; Cornelisse PB; Bruijnen CP; Emmelot M; Sonneveld P; Lokhorst HM; Mutis T; Minnema MC
Blood; 2011 Sep; 118(9):2413-9. PubMed ID: 21690556
[TBL] [Abstract][Full Text] [Related]
3. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial.
Durie BGM; Hoering A; Abidi MH; Rajkumar SV; Epstein J; Kahanic SP; Thakuri M; Reu F; Reynolds CM; Sexton R; Orlowski RZ; Barlogie B; Dispenzieri A
Lancet; 2017 Feb; 389(10068):519-527. PubMed ID: 28017406
[TBL] [Abstract][Full Text] [Related]
4. Lenalidomide alone or in combination with dexamethasone is highly effective in patients with relapsed multiple myeloma following allogeneic stem cell transplantation and increases the frequency of CD4+Foxp3+ T cells.
Minnema MC; van der Veer MS; Aarts T; Emmelot M; Mutis T; Lokhorst HM
Leukemia; 2009 Mar; 23(3):605-7. PubMed ID: 18784738
[No Abstract] [Full Text] [Related]
5. Successful salvage therapy using lenalidomide in a patient with relapsed multiple myeloma after allogeneic hematopoietic stem cell transplantation.
Suzuki T; Kusumoto S; Yoshida T; Mori F; Ito A; Ri M; Ishida T; Komatsu H; Niimi A; Iida S
Int J Hematol; 2013 Apr; 97(4):540-3. PubMed ID: 23456263
[No Abstract] [Full Text] [Related]
6. Lenalidomide maintenance for high-risk multiple myeloma after allogeneic hematopoietic cell transplantation.
Alsina M; Becker PS; Zhong X; Adams A; Hari P; Rowley S; Stadtmauer EA; Vesole DH; Logan B; Weisdorf D; Qazilbash M; Popplewell LL; McClune B; Bensinger W; Riches M; Giralt SA; Pasquini MC;
Biol Blood Marrow Transplant; 2014 Aug; 20(8):1183-9. PubMed ID: 24769014
[TBL] [Abstract][Full Text] [Related]
7. Lenalidomide plus donor-lymphocytes infusion after allogeneic stem-cell transplantation with reduced-intensity conditioning in patients with high-risk multiple myeloma.
El-Cheikh J; Crocchiolo R; Furst S; Ladaique P; Castagna L; Faucher C; Granata A; Oudin C; Lemarie C; Calmels B; Stoppa AM; Schiano De Colella JM; Duran S; Chabannon C; Blaise D
Exp Hematol; 2012 Jul; 40(7):521-7. PubMed ID: 22446605
[TBL] [Abstract][Full Text] [Related]
8. Lenalidomide can induce long-term responses in patients with multiple myeloma relapsing after multiple chemotherapy lines, in particular after allogeneic transplant.
Spina F; Montefusco V; Crippa C; Citro A; Sammassimo S; Olivero B; Gentili S; Galli M; Guglielmelli T; Rossi D; Falcone AP; Grasso M; Patriarca F; De Muro M; Corradini P
Leuk Lymphoma; 2011 Jul; 52(7):1262-70. PubMed ID: 21534872
[TBL] [Abstract][Full Text] [Related]
9. [Graft-versus-host disease associated with lenalidomide maintenance after allogeneic transplantation for relapsed/refractory multiple myeloma].
Tsukada N; Shingaki S; Ikeda M; Miyazaki K; Meshitsuka S; Yoshiki Y; Abe Y; Suzuki K
Rinsho Ketsueki; 2015 Jul; 56(7):895-900. PubMed ID: 26256927
[TBL] [Abstract][Full Text] [Related]
10. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma.
Attal M; Lauwers-Cances V; Marit G; Caillot D; Moreau P; Facon T; Stoppa AM; Hulin C; Benboubker L; Garderet L; Decaux O; Leyvraz S; Vekemans MC; Voillat L; Michallet M; Pegourie B; Dumontet C; Roussel M; Leleu X; Mathiot C; Payen C; Avet-Loiseau H; Harousseau JL;
N Engl J Med; 2012 May; 366(19):1782-91. PubMed ID: 22571202
[TBL] [Abstract][Full Text] [Related]
11. Postallograft lenalidomide induces strong NK cell-mediated antimyeloma activity and risk for T cell-mediated GvHD: Results from a phase I/II dose-finding study.
Wolschke C; Stübig T; Hegenbart U; Schönland S; Heinzelmann M; Hildebrandt Y; Ayuk F; Atanackovic D; Dreger P; Zander A; Kröger N
Exp Hematol; 2013 Feb; 41(2):134-142.e3. PubMed ID: 23085463
[TBL] [Abstract][Full Text] [Related]
12. Stem cell transplantation in multiple myeloma: impact of response failure with thalidomide or lenalidomide induction.
Gertz MA; Kumar S; Lacy MQ; Dispenzieri A; Dingli D; Hayman SR; Buadi FK; Hogan WJ
Blood; 2010 Mar; 115(12):2348-53; quiz 2560. PubMed ID: 20089967
[TBL] [Abstract][Full Text] [Related]
13. Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients.
Gay F; Hayman SR; Lacy MQ; Buadi F; Gertz MA; Kumar S; Dispenzieri A; Mikhael JR; Bergsagel PL; Dingli D; Reeder CB; Lust JA; Russell SJ; Roy V; Zeldenrust SR; Witzig TE; Fonseca R; Kyle RA; Greipp PR; Stewart AK; Rajkumar SV
Blood; 2010 Feb; 115(7):1343-50. PubMed ID: 20008302
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
[TBL] [Abstract][Full Text] [Related]
15. Management of the relapsed/refractory myeloma patient: strategies incorporating lenalidomide.
Richardson P
Semin Hematol; 2005 Oct; 42(4 Suppl 4):S9-15. PubMed ID: 16344100
[TBL] [Abstract][Full Text] [Related]
16. Allogeneic stem cell transplantation in multiple myeloma relapsed after autograft: a multicenter retrospective study based on donor availability.
Patriarca F; Einsele H; Spina F; Bruno B; Isola M; Nozzoli C; Nozza A; Sperotto A; Morabito F; Stuhler G; Festuccia M; Bosi A; Fanin R; Corradini P
Biol Blood Marrow Transplant; 2012 Apr; 18(4):617-26. PubMed ID: 21820394
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of thalidomide therapy for extramedullary relapse of myeloma following allogeneic transplantation.
Biagi JJ; Mileshkin L; Grigg AP; Westerman DW; Prince HM
Bone Marrow Transplant; 2001 Dec; 28(12):1145-50. PubMed ID: 11803357
[TBL] [Abstract][Full Text] [Related]
18. Lenalidomide after stem-cell transplantation for multiple myeloma.
McCarthy PL; Owzar K; Hofmeister CC; Hurd DD; Hassoun H; Richardson PG; Giralt S; Stadtmauer EA; Weisdorf DJ; Vij R; Moreb JS; Callander NS; Van Besien K; Gentile T; Isola L; Maziarz RT; Gabriel DA; Bashey A; Landau H; Martin T; Qazilbash MH; Levitan D; McClune B; Schlossman R; Hars V; Postiglione J; Jiang C; Bennett E; Barry S; Bressler L; Kelly M; Seiler M; Rosenbaum C; Hari P; Pasquini MC; Horowitz MM; Shea TC; Devine SM; Anderson KC; Linker C
N Engl J Med; 2012 May; 366(19):1770-81. PubMed ID: 22571201
[TBL] [Abstract][Full Text] [Related]
19. The graft-versus-myeloma effect: chronic graft-versus-host disease but not acute graft-versus-host disease prolongs survival in patients with multiple myeloma receiving allogeneic transplantation.
Donato ML; Siegel DS; Vesole DH; McKiernan P; Nyirenda T; Pecora AL; Baker M; Goldberg SL; Mato A; Goy A; Rowley SD
Biol Blood Marrow Transplant; 2014 Aug; 20(8):1211-6. PubMed ID: 24792872
[TBL] [Abstract][Full Text] [Related]
20. Lenalidomide is effective as salvage therapy in refractory or relapsed multiple myeloma: analysis of the Spanish Compassionate Use Registry in advanced patients.
Alegre A; Aguado B; Giraldo P; Ríos E; Cánovas A; Ibáñez Á; Castillo I; Hernández MT; Oriol A; Palomera L; Rodríguez JN; García FL; Calvo JM; Martínez-Chamorro C; de la Serna J; Lahuerta JJ
Int J Hematol; 2011 Mar; 93(3):351-360. PubMed ID: 21360065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
